Spyre Therapeutics Inc. (SYRE)
NASDAQ: SYRE
· Real-Time Price · USD
16.46
-0.30 (-1.79%)
At close: Oct 01, 2025, 3:59 PM
16.78
1.94%
After-hours: Oct 01, 2025, 07:13 PM EDT
-1.79% (1D)
| Bid | 16.37 |
| Market Cap | 994.2M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -206.81M |
| EPS (ttm) | -2.61 |
| PE Ratio (ttm) | -6.31 |
| Forward PE | -5.17 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 16.53 |
| Volume | 543,773 |
| Avg. Volume (20D) | 560,704 |
| Open | 16.73 |
| Previous Close | 16.76 |
| Day's Range | 16.37 - 17.18 |
| 52-Week Range | 10.91 - 40.26 |
| Beta | 2.88 |
| Ex-Dividend Date | n/a |
About SYRE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SYRE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SYRE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-11.64%
SYRE stock has given up its prior gain. Spyre Ther...
Unlock content with
Pro Subscription
3 months ago
-11.64%
Spyre Therapeutics shares are trading higher after the company announced interim Phase 1 results from its first-in-human trials of SPY002 and SPY072.
1 week ago · seekingalpha.com
Intelligent Development Could Make Spyre Therapeutics Best In ShowSpyre Therapeutics has multiple potential best-in-class antibodies in its pipeline to treat ulcerative colitis, a trial design that tests combinations of these antibodies, and cash to run that trial. ...